Relay Therapeutics, Inc.

small molecule precision medicines (computational structure-based drug discovery)

RLAY · Nasdaq · United States

Share price · RLAY

$16.51-4.10 (-19.89%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.4M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RLAY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+9.6%
  2. 6 Nov 2026+9.4%
  3. 30 Oct 2026-5.8%

    Nothing announced by RLAY that day or the session before.

  4. 20 Oct 2026+8.0%
  5. 21 Sep 2026-3.5%
  6. 2 Jun 2026+10.1%
  7. 28 Apr 2026-12.8%
  8. 7 Apr 2026+8.3%

    Nothing announced by RLAY that day or the session before.

  9. 2 Apr 2026+16.4%
  10. 1 Apr 2026+8.2%

Share of unusual movement by asset

For each asset, the share of RLAY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zovegalisib
events and moves
7shown from 8 days
lirafugratinib (Lyrfigtu)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—31%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—60%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
lirafugratinib(Lyrfigtu)
Approved
FGFR2Small molecule
Biliary Tract Cancer
Cholangiocarcinoma
Phase 3
PI3K-alpha (mutant-selective)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
lirafugratinib · LyrfigtuPhase 2FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Est. primary completion 2027-09 · NCT07359820 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
ZovegalisibPhase 3PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer …
Est. primary completion 2028-04-30 · NCT06982521 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
ZovegalisibPhase 2PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome …
Est. primary completion 2031-07 · NCT06789913 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 September 2026ApprovallirafugratinibFDA approves Lyrfigtu in previously treated FGFR2-altered cholangiocarcinoma
US, FDA · Elevar Therapeutics, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$77M$125M$82M-$64M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.3M$76M$123M$84M-$54M operating cash flowreport ↗
2026-Q1$3.0M$71M$206M$73M-$51M operating cash flowreport ↗
2025-Q3$0$68M$94M$74M-$62M operating cash flowreport ↗
2025-Q2$0.7M$64M$116M$70M-$55M operating cash flowreport ↗
2025-Q1$7.7M$74M$96M$77M-$73M operating cash flowreport ↗
2024-Q3$0$77M$154M$88M-$75M operating cash flowreport ↗
2024-Q2$0$92M$137M$92M-$66M operating cash flowreport ↗
2024-Q1$10M$82M$156M$81M-$50M operating cash flowreport ↗
2023-Q3$25M$81M$154M$66M-$75M operating cash flowreport ↗
2023-Q2$0.1M$88M$149M$99M-$69M operating cash flowreport ↗
2023-Q1$0.2M$83M$164M$94M-$67M operating cash flowreport ↗
2022-Q3$0.3M$67M$357M$84M-$66M operating cash flowreport ↗
2022-Q2$0.4M$61M$110M$77M-$57M operating cash flowreport ↗
2022-Q1$0.4M$52M$122M$62M-$49M operating cash flowreport ↗
2021-Q3$0.7M$45M$231M$61M-$53M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$15M$261M$85M$69M-$235M operating cash flowreport ↗

Relay Therapeutics reported full-year 2025 revenue of $15.36M, up 53.4% YoY, while R&D expenses declined 18.1% YoY to $261.38M. The company ended the period with cash, cash equivalents, and investments of approximately $554.5M and reported a net loss of $276.5M, or $1.61 per share.

The company guided that its current cash position is expected to fund operations into 2029. Anticipated 2026 milestones include initial Phase 1 data for zovegalisib in PIK3CA-driven vascular anomalies in the first half of 2026, breast cancer triplet data and frontline Phase 3 plans during 2026, and presentation of initial Phase 1/2 data for zovegalisib plus fulvestrant at the Phase 3 dose at ESMO TAT on March 16, 2026. Zovegalisib recently received Breakthrough Therapy designation from the FDA.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10M$319M$126M$84M-$249M operating cash flowreport ↗
2023-FY$26M$330M$146M$85M-$300M operating cash flowreport ↗
2022-FY$1.4M$246M$154M$73M-$229M operating cash flowreport ↗
2021-FY$3.0M$173M$283M$91M-$74M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 39 sales ($129.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-28Catinazzo Thomas · Chief Financial OfficerOpen-market sale1,469$18.62$27KForm 4
2026-10-28Bergstrom Donald A · President, R&DOpen-market sale2,252$18.62$42KForm 4
2026-10-28Rahmer Peter · See remarksOpen-market sale753$18.62$14KForm 4
2026-10-07Patel Sanjiv · director, President and CEOOpen-market sale48,199$18.10$872KForm 4
2026-10-06Catinazzo Thomas · Chief Financial OfficerOpen-market sale17,511$18.58$325KForm 4
2026-10-06Catinazzo Thomas · Chief Financial OfficerOpen-market sale206$19.26$4KForm 4
2026-09-08Patel Sanjiv · director, President and CEOOpen-market sale48,199$18.94$913KForm 4
2026-09-08Catinazzo Thomas · Chief Financial OfficerOpen-market sale17,717$18.94$336KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 241 reporting institutions held 184.6M shares ($1.8B, 83.5% of shares outstanding).

#InstitutionSharesValue
1SB INVESTMENT ADVISERS (UK) LTD27,904,963$277.7M
2Commodore Capital LP17,000,000$169.2M
3Casdin Capital, LLC14,418,574$143.5M
4BlackRock, Inc.12,975,299$129.1M
5PERCEPTIVE ADVISORS LLC9,751,141$97.0M
6Bellevue Group AG7,795,242$77.6M
7VANGUARD CAPITAL MANAGEMENT LLC7,387,465$73.5M
8STATE STREET CORP6,233,545$62.0M
9Nextech Invest, Ltd.5,526,506$55.0M
10TCG Crossover Management, LLC4,273,356$42.5M
11FMR LLC3,695,431$36.8M
12GEODE CAPITAL MANAGEMENT, LLC3,510,636$34.9M
13Balyasny Asset Management L.P.3,039,179$30.2M
14Spruce Street Capital LP2,984,125$29.7M
15DIMENSIONAL FUND ADVISORS LP2,940,536$29.2M